The Cell & Gene therapy investor day provides investors with unique insight into financing opportunities for cell and gene therapy-based treatment and tools.
BioTrinity offers unique access to investors, big pharma executives and innovative CEO's of emerging R&D companies seeking to strike deals and grow their networks.
Lentviral and retroviral vectors are at the forefront of advanced therapeutic medicinal product (ATMP) development.
The American Society of Gene & Cell Therapy is the primary professional membership organization for gene and cell therapy. The Society's members are scientists, physicians, patient advocates, and other professionals.
As product developers move toward second generation gene and cell medicine constructs, the importance of novel gene regulation and promoter elements has emerged.